Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 702-710

  Scordo, Maria Gabriella ^a,b,c   Pengo, Vittorio ^a,b,c   Spina, Edoardo ^a,b,c   Dahl, Marja Liisa ^a,b,c   Gusella, Milena ^a,b,c   Padrini, Roberto ^a,b,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICONVULSIVE AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; RIFAMPICIN; SULFONAMIDE; WARFARIN;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CALCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; EQUILIBRIUM DIALYSIS; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEREDITY; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; INTERNATIONAL STANDARD UNIT; ITALY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SIDE EFFECT; VALVULAR HEART DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; ISOMERISM; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RESTRICTION MAPPING; WARFARIN;

EID: 0036914221     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129321     Document Type: Article

References (31)

1. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
2. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data. Pharmacogenetics 2002;12:251-63.
3. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1995; 108(Suppl):231-46.
4. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complications. Lancet 1999;353:717-9.
5. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96;1816-9.
6. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986;11:483-504.
7. Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994;56:286-94.
8. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
9. Mines JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
10. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of CYP2C9-Leu359 allele variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
11. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
12. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allele variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
13. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allele variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
14. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a Black African population. Br J Clin Pharmacol 2001;52:447-50.
15. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, et al. Comparison between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:365-73.
16. Margaglione M, Colaizzo D, D'Andera G, Brancaccio V, Ciampa A, Grandone E, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84:775-8.
17. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes: A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996;24:610-4.
18. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999;254:628-31.
19. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
20. Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl 1998;710:143-8.
21. Banefield C, O'Reilly R, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man: Further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983;16:669-75.
22. Huang J. Errors in estimating the unbound fraction of drugs to the volume shift in equilibrium dialysis. J Pharm Sci 1983;72:1368-9.
23. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart diseases having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-28.
24. Wilkinson GR, Shand DG. A physiologic approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18: 377-90.
25. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000;128: 281-5.
26. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-10.
27. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulant therapy. Pharmacogenetics 1995;5:389-92.
28. O'Reilly RA. Studies on the optical enantiomers of warfarin in man. Clin Pharmacol Ther 1974;16:348-54.
29. Levy G, O'Reilly RA, Wingard LB. Relationship between kinetics of anticoagulant effects of racemic warfarin and its individual enantiomers in man. Res Commun Chem Pathol Pharmacol 1974;7:359-65.
30. Leung AY, Chow HC, Kwong YL, Lie AK, Fung AT, Chow WH, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001;98: 2584-7.
31. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990;46:377-94.